The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
Official Title: A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
Study ID: NCT01024504
Brief Summary: This trial will evaluate the efficacy and safety of the capecitabine and oxaliplatine plus bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer.
Detailed Description: Capecitabine, oxaliplatin and bevacizumab are well known active agents in the treatment of mCRC. The treatment of elderly patients with mCRC is an area of investigation. The role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation.
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, , Greece
Air Forces Military Hospital of Athens, Athens, , Greece
IASO General Hospital of Athens, 1st Dep of Medical Oncology, Athens, , Greece
Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, , Greece
State General Hospital of Larissa, Larissa, , Greece
Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, , Greece
Name: John Souglakos, MD
Affiliation: University Hospital of Crete, Dep of Medical Oncology
Role: PRINCIPAL_INVESTIGATOR
Name: Lampros Vamvakas, MD
Affiliation: University Hospital of Crete
Role: PRINCIPAL_INVESTIGATOR